宿迁联盛科技股份有限公司2025 年半年度报告 公司代码：603065 公司简称：宿迁联盛 宿迁联盛科技股份有限公司 宿迁联盛科技股份有限公司2025 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、本半年度报告未经审计。 四、公司负责人林俊义、主管会计工作负责人李利及会计机构负责人（会计主管人员）苗田声明： 保证半年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，该前 瞻性陈述受制于已知及未知的风险、不确定性及其他因素，因而可能造成本公司的实际表现、财 务状况或经营业绩与该前瞻性陈述所暗示的任何未来表现、财务状况或经营业绩存有重大不同， 敬请投资者注意投资风险。 七、是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担 ...

| 证券代码：603065 证券简称：宿迁联盛 | | | | | | | 公告编号：2025-055 | | --- | --- | --- | --- | --- | --- | --- | --- | | 宿迁联盛科技股份有限公司 | | | | | | | | | 关于 2025 年半年度主要经营数据的公告 | | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | | | | 宿迁联盛科技股份有限公司（以下简称"公司"）主营业务为高分子材料防 | | | | | | | | | 老化助剂及其中间体的研发、生产与销售，根据上海证券交易所发布的《上海证 | | | | | | | | | 3 号行业信息披露：第十三号——化工》及相 券交易所上市公司自律监管指引第 | | | | | | | | | 关要求，现将公司 2025 年半年度主要业务板块经营数据披露如下： | | | | | | | | | 一、主要产品的产量、销量及收入实现情况 ...

证券代码：603065 证券简称：宿迁联盛 公告编号：2025-055 宿迁联盛科技股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宿迁联盛科技股份有限公司（以下简称"公司"）主营业务为高分子材料防 老化助剂及其中间体的研发、生产与销售，根据上海证券交易所发布的《上海证 券交易所上市公司自律监管指引第 3 号行业信息披露：第十三号——化工》及相 关要求，现将公司 2025 年半年度主要业务板块经营数据披露如下： 注：中间体生产主要用途为自用。 二、主要化工产品和原材料的价格变动情况 （一）2025 年半年度公司主要化工产品价格变动情况（不含税） | 主要产品 | | | 平均售价（万元/吨） | | | 同比变动比率 （%） | 环比变动比率 （%） | | --- | --- | --- | --- | --- | --- | --- | --- | | | 年 2025 | 1-6 | 月 | 年 2024 1-6 | 月 | | | | 受阻胺光稳定剂 | 4.3 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600352 证券简称：浙江龙盛 公告编号：2025-035 号 浙江龙盛集团股份有限公司 2025 年上半年度主要经营数据公告 根据上海证券交易所《上市公司自律监管指引第 3 号——行业信息披露》的 要求，公司现将 2025 年上半年度主要经营数据披露如下： 注：上述产品销量包含了部分外购成品再销售的量。 二、主要产品和原材料的价格变动情况 （一）主要产品价格(不含增值税)波动情况 第 1页 共 4 页 一、主要产品的产量、销量及收入实现情况 主要 产品 2025年4－6月 2025年1－6月 产量 （吨） 销量 （吨） 营业收入（元） 产量 （吨） 销量 （吨） 营业收入（元） 染料 54,306 59,473 1,859,659,789.51 110,710 115,383 3,631,784,713.05 助剂 10,522 15,706 234,878,202.54 21,282 31,154 476,688,401.89 中间体 30,566 22,951 ...

Core Viewpoint - The company is enhancing its strategic focus on major clients by establishing a dedicated service team to improve customer response efficiency and satisfaction, while expanding its collaboration with multinational corporations (MNCs) across the entire drug development cycle [1] Group 1: Strategic Initiatives - The company has initiated a major client strategy since last year, forming a "triangular" business team consisting of client managers, solution managers, and delivery managers to provide in-depth services to strategic clients [1] - A specialized major client service team has been established this year to coordinate business development resources across regions including China, the US, and Europe, significantly improving customer response efficiency and satisfaction [1] Group 2: Collaboration with MNCs - The collaboration with MNCs has evolved from supplying molecular building blocks to a comprehensive CMC (Chemistry, Manufacturing, and Controls) service, with increasing depth and project scale [1] - The company now covers the entire R&D cycle for MNCs, including drug discovery, clinical development, and CMC services from clinical phases I-III to commercialization [1] Group 3: Innovation and Project Development - The company is leveraging its solid foundation of cooperation and client trust to enter the new molecular pipeline development field for MNCs, with ongoing projects in cutting-edge areas such as peptides (non-natural amino acid building blocks) and ADC (antibody-drug conjugates) design [1] - The company is continuously deepening its collaborative efforts in innovative therapies [1]

Group 1 - The company has confirmed that all its constructed projects have production capabilities [2] - The specific product, Ammonium Chloride Dimethyl Benzamide, has not yet commenced production, while other intermediates and raw drug projects are already in production [2]

Group 1 - The core point of the article is that Hongyang (000525) has confirmed that all its established projects are operational, with the exception of the production of ammonium chlorodimethylbenzamide, which has not yet commenced [1] - The company has successfully launched production for other intermediates and active pharmaceutical ingredient projects [1]

Core Viewpoint - Guangkang Biochemical (300804) focuses on the research, production, and sales of pesticide raw materials, intermediates, and formulations, with some products showing effectiveness in mosquito control [1] Company Overview - The company has not obtained the necessary registration qualifications for health pesticides, which are required for products used in public health pest control [1] - The company emphasizes the need to comply with relevant laws and regulations when using its products in the health pest control sector [1]

Group 1: Report Overview - The research object is Gongtong Pharmaceutical Co., Ltd., belonging to the chemical pharmaceutical industry, and the reception time was on June 12, 2025 [16]. - The participants in the research include investors who participated in the "2025 Online Collective Reception Day for Investors of Listed Companies in Hubei Province" [19]. Group 2: Company's Market Position and Strategy - In the field of steroid drug starting materials, the company has achieved large - scale production of a full range of products such as 4 - androstenedione (4 - AD), androstadienedione (ADD), 9 - hydroxyandrostenedione (9 - OH - AD), 11 - hydroxy - AD, and dihydroxyalcohol, with its production capacity scale and product variety diversity ranking among the top in the world; in the intermediate field, it has built a vertically integrated system covering the entire steroid drug industry chain and has become an important R & D and production base for steroid drug intermediates in China; in the API field, relying on the API project of its subsidiary Huahai Gongtong, it will become the first integrated supplier in China to simultaneously layout sex hormones, progestogens, corticosteroids, and other types of steroid APIs, realizing the full - chain connection from starting materials to APIs [23]. - To face market competition, the company adheres to innovation - driven development, with its product strategy focusing on three directions: deepening the integration of biotransformation and synthetic biology technologies through technological iteration to reduce the production cost of key intermediates; optimizing the automation level of existing production lines through capacity expansion to increase the proportion of high - value - added product production capacity; and continuously exploring the market, consolidating strategic cooperation with global leading pharmaceutical companies, and expanding the layout of intermediates in emerging fields such as anti - cancer and assisted reproduction [23]. Group 3: R & D - related Information - The Hubei Gongtong Steroid Research Institute, established over three years ago, aims to break through four core technologies: targeted screening of strains, targeted modification of enzyme engineering, efficient conversion of sterols, and green synthesis processes, and form a closed - loop innovation system from basic research to industrial transformation. Its technological achievements have won many authoritative certifications such as the National Science and Technology Progress Award [24][25]. - From 2022 to 2024, the company's R & D investments were 45.15 million yuan, 38.10 million yuan, and 51.08 million yuan respectively, and the proportion of R & D investment in operating income has been increasing year by year. The company has established a special R & D center to promote the R & D of new products and processes and the upgrading and optimization of existing processes [25]. Group 4: Overseas Market and Other Business Information - In 2024, the company's overseas sales accounted for 28.54%, and the proportion has been increasing year by year. In 2025, the company will continue to adhere to the international development strategy, strengthen brand promotion overseas and increase sales channels by establishing subsidiaries overseas, and seek business cooperation through overseas resources [25]. - The vitamin D3 industrialization project has been filed and is being implemented according to the company's project plan [27]. - Regarding the company's share repurchase, the period is within 12 months from the date of the board of directors' review. The company will promote the repurchase work according to market conditions and disclose the repurchase progress as of the end of the previous month at the beginning of each month [27]. - For specific information on innovative drugs such as fluvestrant, it shall be subject to the information disclosed on the company's designated information disclosure website; for the follow - up plan of convertible bonds, it shall be subject to the company's announcements; and for the question of whether the company's losses in the first half of the year will increase year - on - year after the capitalization of the raised projects, it is necessary to refer to the semi - annual report of 2025 [25][27]

Group 1: Market Position and Strategy - The company has achieved large-scale production of steroid drug starting materials, ranking among the top globally in terms of production capacity and variety [2] - It has established a vertically integrated system covering the entire steroid drug industry chain, becoming a key R&D and production base for steroid drug intermediates in China [3] - The company focuses on three strategic directions: reducing production costs through technological iteration, optimizing existing production lines to increase high-value product capacity, and expanding market presence in emerging fields like anti-cancer and assisted reproduction [3] Group 2: R&D Investment and Achievements - R&D investments from 2022 to 2024 were 45.15 million, 38.10 million, and 51.08 million CNY, respectively, with the proportion of R&D investment to revenue increasing year by year [4] - The company has established a closed-loop innovation system from basic research to industrialization, recognized with multiple awards including the National Science and Technology Progress Award [3] Group 3: International Market Expansion - In 2024, the company's product export ratio was 28.54%, showing a year-on-year increase [3] - Plans for 2025 include strengthening brand promotion and sales channels through overseas subsidiaries and seeking commercial cooperation through international resources [3] Group 4: Stock Performance and Future Plans - The company is considering stock repurchase based on market conditions, with updates provided monthly [5] - There are ongoing projects for innovative drugs, including the industrialization of Vitamin D3, which is progressing as planned [5]